Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

PF4V1 (Platelet Factor 4 Variant 1)

Written2014-06Katrien Van Raemdonck, Paul Proost, Jo Van Damme, Sofie Struyf
Laboratory of Molecular Immunology, Rega Institute for Medical Research, Department of Microbiology, Immunology, KU Leuven, Leuven, Belgium

(Note : for Links provided by Atlas : click)


HGNC (Hugo) PF4V1
HGNC Alias symbSCYB4V1
LocusID (NCBI) 5197
Atlas_Id 44606
Location 4q13.3  [Link to chromosome band 4q13]
Location_base_pair Starts at 73853296 and ends at 73854483 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping PF4V1.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
Note The CXC chemokine CXCL4L1 is a nonallelic variant of the earlier identified platelet factor CXCL4. These rather atypical chemokines display a less prominent leukocyte chemoattractant activity, yet influence a large range of other processes. CXCL4L1 was characterized as an especially potent angiostatic chemokine (Struyf et al., 2004). Consequently, this platelet factor is an inhibitor of tumor growth and metastasis. The therapeutic potential of CXCL4L1 has been evidenced in preclinical B16 melanoma, Lewis lung carcinoma and A549 adenocarcinoma animal models, as it inhibited both tumor growth and metastasis by preventing tumor neovascularization (Struyf et al., 2007). Furthermore, the carboxy-terminal peptide CXCL4L147-70 retains its potential to suppress B16 melanoma growth in mice (Vandercappellen et al., 2010). Additionally, the recently highlighted impact of CXCL4L1 on lymphatic endothelial cells in vitro, corroborates a potential inhibitory effect on tumor dissemination in vivo (Prats et al., 2013; Van Raemdonck et al., 2014). Compared to CXCL4, the affinity of CXCL4L1 for glycosaminoglycans (GAG) is rather moderate (Dubrac et al., 2010; Struyf et al., 2011), strongly increasing its in vivo half-life and diffusibility.


Note The gene and mRNA for CXCL4L1 are 1293 and 741 bp in length, respectively.
  Figure 1. Structure of the human CXCL4L1 gene. This figure schematically depicts the structure of the human CXCL4L1 gene as described in the NCBI database (NM_002620). Lines represent the introns, whereas rectangular exons are coloured blue, yellow and green to represent the non-coding domains, the signal peptide and the mature protein, respectively. Grey numbers indicate the basepairs (bp) spanning the exons. Red numbers apply to the amino acids (aa) encoded.
Description The CXCL4L1 mRNA is encoded by three exons. Duplication of the CXCL4 gene, giving rise to the homologous CXCL4L1 gene, is conserved in human and other primates including gorilla, chimpanzee, orangutan, gibbon and macaque.
Transcription The existence of a CXCL4 variant was first evidenced by Eisman et al. (1990) and Green et al. (Eisman et al., 1990; Green et al., 1989). The CXCL4L1 mRNA is predominantly present in platelets, but has also been detected in vascular smooth muscle cells and to a lesser extent in T cells, monocytes and endothelial cells (Lasagni et al., 2007). CXCL4L1 mRNA detected in ovarian tissue has been attributed to macrophage CXCL4L1 expression (Furuya et al., 2012). CXCL4L1 expression was also observed in the HCT-8 colon adenocarcinoma cell line as evidenced by qPCR analysis (Verbeke et al., 2010).
Pseudogene None.


Note CXCL4L1 precursor: 104 amino acids (aa), 11553 Da; CXCL4L1 mature: 70 aa, 7805.8 Da.
Description CXCL4L1 is a member of the CXC chemokine family of chemoattractant cytokines. CXCL4L1 is a non-ELR CXC chemokine, meaning that it lacks the sequence glutamic acid-leucine-arginine just in front of the two NH2-terminally located conserved cysteine residues.
Expression Blood platelets release both CXCL4 and CXCL4L1 after activation. The exact location of CXCL4L1 inside the platelet is not yet determined, whereas platelet CXCL4 is stored in the alpha-granules. In other cell types as well, CXCL4 is stored in secretory granules and released in response to protein kinase C activation, whereas CXCL4L1 is continuously synthesized and secreted through a constitutive pathway (Lasagni et al., 2007). For instance, human aortic smooth muscle cells and human coronary smooth muscle cells constitutively release CXCL4L1. Specific cancer cell lines have also been shown to produce CXCL4L1. Secretion of CXCL4L1 in tumoral tissue was evidenced in vitro on stimulated osteosarcoma cells through the use of ELISA and further corroborated by immunohistochemical staining of different human sarcoma tissue sections (osteosarcoma, leiomyosarcoma and liposarcoma) (Vandercappellen et al., 2007). Furthermore, CXCL4L1 was strongly detected in colorectal adenocarcinoma biopsy specimens (Verbeke et al., 2010).
Localisation Secreted.
Function CXCL4L1 has been described to be a strong inhibitor of angiogenesis. Together with its potential to chemoattract T cells, natural killer cells and immature dendritic cells, the vascular effects contribute to the antitumoral action of CXCL4L1 (Struyf et al., 2011). Struyf et al. (Struyf et al., 2007) indeed indicated the angiostatic platelet factor to exert an antitumoral effect by inhibiting branching of the vascular network and metastasis. Considering neutrophils and monocytes, CXCL4L1 as opposed to CXCL4 would not attract these pro-tumoral phagocytes (Vandercappellen et al., 2007).
Lasagni et al. identified a splice variant of CXCR3, which was named CXCR3B, as a functional GPCR for CXCL4 (Lasagni et al., 2003). Currently, both CXCL4 and CXCL4L1 are known to activate CXCR3A, as well as CXCR3B (Mueller et al., 2008; Struyf et al., 2011; Van Raemdonck et al., 2014). In general, proliferative and positive migratory effects are supposed to be mediated by CXCR3A, whereas inhibition of chemotaxis, anti-proliferative and apoptotic effects are postulated to be provoked via CXCR3B (Lasagni et al., 2003). Besides endothelial cells and T cells, CXCR3 expressing cell types can be extended to fibroblasts, mesangial cells, airway epithelial and smooth muscle cells, pneumocytes and several sarcoma, carcinoma and myeloma cell types (Billottet et al., 2013).
CXCL4 exerts its action through many different mechanisms, including binding to GAG and heteromultimerisation with other chemokines and growth factors, whereas in the case of CXCL4L1 its distorted structure and unique protruding C-terminal helix are assumed to conflict with this mode of action. The open formation characteristic of CXCL4L1 decreases GAG-binding, however simultaneously enhancing anti-angiogenic and anti-tumoral effects (Dubrac et al., 2010; Kuo et al., 2013). Additionally, CXCL4L1 forms more stable homodimers due to a loss in positive charge. This gained stability is likely to interfere with the ability to form heteromers which requires initial dissociation of the homomultimers (Kuo et al., 2013).
Homology CXCL4L1 is a non-allelic variant of CXCL4. Unlike CXCL4, its variant appears only in primates. In men, mature proteins only differ in 3 amino acids. On the other hand, the signal peptide of human CXCL4L1 displays 38% amino acid divergence compared to human CXCL4, affecting its subcellular localization and regulated secretion mechanism, as was described by Lasagni et al. (Lasagni et al., 2007).

Implicated in

Entity Osteosarcoma
Disease Secretion of CXCL4L1 in tumoral tissue was evidenced in vitro on stimulated osteosarcoma cells through the use of ELISA and further corroborated by immunohistochemical staining of different human sarcoma tissue sections (osteosarcoma, leiomyosarcoma and liposarcoma) (Vandercappellen et al., 2007). On the other hand, osteosarcoma cells also express the CXCR3 receptor guiding initial tumor dissemination to metastatic sites were CXCR3 ligands such as CXCL4L1 are expressed (Pradelli et al., 2009).
Entity Colorectal cancer
Disease Study of CXCL4L1 expression in human epithelial tumors revealed a distinct presence of CXCL4L1 in colorectal cancer cells, whereas its expression in esophageal cancer was weak to undetectable (Verbeke et al., 2010). ELISA, qRT-PCR, immunocytochemistry as well as ex vivo immunohistochemistry support the hypothesis that CXCL4L1 is secreted by colorectal adenocarcinoma cells and may affect the complex process of tumor development. However, no correlation was found between the intensity or extent of CXCL4L1 staining of patient biopsies and the TNM stage. On the other hand, intratumorally administered CXCL4L1 has been shown to reduce tumor vascularization and, consequently, tumor growth and metastasis of A549 adenocarcinoma in mice, similar to its therapeutic benefit observed in preclinical studies on B16 melanoma and Lewis lung carcinoma (Struyf et al., 2007).
Entity Endometriosis-associated ovarian cancer (EAOC)
Oncogenesis Both clear cell and endometrioid types of ovarian cancers occasionally develop on the bases of endometriosis. CXCL4L1 is expressed in normal ovaries and especially during endometriosis (Furuya et al., 2012). However, CXCL4L1 mRNA levels were significantly lower in cancerous lesions. Endometriosis-associated ovarian cancers (EAOC) were reported to be infiltrated by CD68+ tumor-associated macrophages. CXCL4 and CXCL4L1 expression by those macrophages was studied at the protein level by Furuya and colleagues. However, antibodies not distinguishing CXCL4 from its variant were used. The tumor-associated macrophages displayed an impaired expression of either CXCL4, CXCL4L1 or possibly both. In conclusion, macrophage expression of the platelet factors appears to be associated with EAOC disease state and may prove to be a useful disease marker.
Entity Coronary artery disease
Prognosis Recently, a possible prognostic significance for CXCL4L1 was evaluated in patients suffering from coronary artery disease (CAD) (De Sutter et al., 2012). Specifically in a selection of patients with stable CAD and preserved left ventricular function, CXCL4L1 levels significantly correlated to age, creatinine and circulating platelet number, as well as to N-terminal pro-B-type natriuretic peptide (NT-proBNP), a well validated prognostic marker in stable CAD. More importantly, CXCL4L1 showed an additional prognostic value on top of NT-proBNP as lower levels of CXCL4L1 predicted a higher event rate and worse outcome. Surprisingly, in these patients with stable CAD the prognostic value of CXCL4L1 is independent of NT-proBNP.


CXCR3, a double-edged sword in tumor progression and angiogenesis.
Billottet C, Quemener C, Bikfalvi A.
Biochim Biophys Acta. 2013 Dec;1836(2):287-95. doi: 10.1016/j.bbcan.2013.08.002. Epub 2013 Aug 27. (REVIEW)
PMID 23994549
PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function.
De Sutter J, Van de Veire NR, Struyf S, Philippe J, De Buyzere M, Van Damme J.
PLoS One. 2012;7(2):e31343. doi: 10.1371/journal.pone.0031343. Epub 2012 Feb 23.
PMID 22384011
Functional divergence between 2 chemokines is conferred by single amino acid change.
Dubrac A, Quemener C, Lacazette E, Lopez F, Zanibellato C, Wu WG, Bikfalvi A, Prats H.
Blood. 2010 Nov 25;116(22):4703-11. doi: 10.1182/blood-2010-03-274852. Epub 2010 Aug 5.
PMID 20688960
Structural and functional comparison of the genes for human platelet factor 4 and PF4alt.
Eisman R, Surrey S, Ramachandran B, Schwartz E, Poncz M.
Blood. 1990 Jul 15;76(2):336-44.
PMID 1695112
Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis.
Furuya M, Tanaka R, Miyagi E, Kami D, Nagahama K, Miyagi Y, Nagashima Y, Hirahara F, Inayama Y, Aoki I.
Cancer Biol Ther. 2012 Jun;13(8):671-80. doi: 10.4161/cbt.20084. Epub 2012 Jun 1.
PMID 22555803
Identification and characterization of PF4varl, a human gene variant of platelet factor 4.
Green CJ, Charles RS, Edwards BF, Johnson PH.
Mol Cell Biol. 1989 Apr;9(4):1445-51.
PMID 2725510
Alternative C-terminal helix orientation alters chemokine function: structure of the anti-angiogenic chemokine, CXCL4L1.
Kuo JH, Chen YP, Liu JS, Dubrac A, Quemener C, Prats H, Bikfalvi A, Wu WG, Sue SC.
J Biol Chem. 2013 May 10;288(19):13522-33. doi: 10.1074/jbc.M113.455329. Epub 2013 Mar 27.
PMID 23536183
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P.
J Exp Med. 2003 Jun 2;197(11):1537-49.
PMID 12782716
PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion.
Lasagni L, Grepin R, Mazzinghi B, Lazzeri E, Meini C, Sagrinati C, Liotta F, Frosali F, Ronconi E, Alain-Courtois N, Ballerini L, Netti GS, Maggi E, Annunziato F, Serio M, Romagnani S, Bikfalvi A, Romagnani P.
Blood. 2007 May 15;109(10):4127-34. Epub 2007 Jan 11.
PMID 17218382
CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3.
Mueller A, Meiser A, McDonagh EM, Fox JM, Petit SJ, Xanthou G, Williams TJ, Pease JE.
J Leukoc Biol. 2008 Apr;83(4):875-82. doi: 10.1189/jlb.1006645. Epub 2008 Jan 3.
PMID 18174362
Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs.
Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Kleinerman ES, Schmid-Alliana A, Schmid-Antomarchi H.
Int J Cancer. 2009 Dec 1;125(11):2586-94. doi: 10.1002/ijc.24665.
PMID 19544560
CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis.
Prats AC, Van den Berghe L, Rayssac A, Ainaoui N, Morfoisse F, Pujol F, Legonidec S, Bikfalvi A, Prats H, Pyronnet S, Garmy-Susini B.
Microvasc Res. 2013 Sep;89:25-33. doi: 10.1016/j.mvr.2013.05.005. Epub 2013 Jun 4.
PMID 23747987
Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis.
Struyf S, Burdick MD, Peeters E, Van den Broeck K, Dillen C, Proost P, Van Damme J, Strieter RM.
Cancer Res. 2007 Jun 15;67(12):5940-8.
PMID 17575164
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.
Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J.
Blood. 2011 Jan 13;117(2):480-8. doi: 10.1182/blood-2009-11-253591. Epub 2010 Oct 27.
PMID 20980681
CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.
Van Raemdonck K, Gouwy M, Lepers SA, Van Damme J, Struyf S.
Angiogenesis. 2014 Jul;17(3):631-40. doi: 10.1007/s10456-014-9417-6. Epub 2014 Jan 28.
PMID 24469069
The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J.
Mol Cancer Res. 2010 Mar;8(3):322-34. doi: 10.1158/1541-7786.MCR-09-0176. Epub 2010 Mar 9.
PMID 20215425
Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
Verbeke H, De Hertogh G, Li S, Vandercappellen J, Noppen S, Schutyser E, El-Asrar AA, Opdenakker G, Van Damme J, Geboes K, Struyf S.
Hum Pathol. 2010 Jul;41(7):990-1001. doi: 10.1016/j.humpath.2009.09.021. Epub 2010 Mar 23.
PMID 20334899


This paper should be referenced as such :
Raemdonck K Van, P Proost, Damme J Van, S Struyf
PF4V1 (Platelet Factor 4 Variant 1)
Atlas Genet Cytogenet Oncol Haematol. 2015;19(3):198-201.
Free journal version : [ pdf ]   [ DOI ]

External links

HGNC (Hugo)PF4V1   8862
Entrez_Gene (NCBI)PF4V1    platelet factor 4 variant 1
AliasesCXCL4L1; CXCL4V1; PF4-ALT; PF4A; 
GeneCards (Weizmann)PF4V1
Ensembl hg19 (Hinxton)ENSG00000109272 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000109272 [Gene_View]  ENSG00000109272 [Sequence]  chr4:73853296-73854483 [Contig_View]  PF4V1 [Vega]
ICGC DataPortalENSG00000109272
TCGA cBioPortalPF4V1
AceView (NCBI)PF4V1
Genatlas (Paris)PF4V1
SOURCE (Princeton)PF4V1
Genetics Home Reference (NIH)PF4V1
Genomic and cartography
GoldenPath hg38 (UCSC)PF4V1  -     chr4:73853296-73854483 +  4q13.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)PF4V1  -     4q13.3   [Description]    (hg19-Feb_2009)
GoldenPathPF4V1 - 4q13.3 [CytoView hg19]  PF4V1 - 4q13.3 [CytoView hg38]
genome Data Viewer NCBIPF4V1 [Mapview hg19]  
Gene and transcription
Genbank (Entrez)BC130653 BC130657
RefSeq transcript (Entrez)NM_002620
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)PF4V1
Alternative Splicing GalleryENSG00000109272
Gene ExpressionPF4V1 [ NCBI-GEO ]   PF4V1 [ EBI - ARRAY_EXPRESS ]   PF4V1 [ SEEK ]   PF4V1 [ MEM ]
Gene Expression Viewer (FireBrowse)PF4V1 [ Firebrowse - Broad ]
GenevisibleExpression of PF4V1 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)5197
GTEX Portal (Tissue expression)PF4V1
Human Protein AtlasENSG00000109272-PF4V1 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP10720   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP10720  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP10720
Splice isoforms : SwissVarP10720
Domaine pattern : Prosite (Expaxy)SMALL_CYTOKINES_CXC (PS00471)   
Domains : Interpro (EBI)Chemokine_CXC    Chemokine_CXC_CS    Chemokine_IL8-like_dom    CXC_Chemokine_domain    Interleukin_8-like_sf    PF4   
Domain families : Pfam (Sanger)IL8 (PF00048)   
Domain families : Pfam (NCBI)pfam00048   
Domain families : Smart (EMBL)SCY (SM00199)  
Conserved Domain (NCBI)PF4V1
Blocks (Seattle)PF4V1
PDB Europe4HSV   
Structural Biology KnowledgeBase4HSV   
SCOP (Structural Classification of Proteins)4HSV   
CATH (Classification of proteins structures)4HSV   
Human Protein Atlas [tissue]ENSG00000109272-PF4V1 [tissue]
Peptide AtlasP10720
Protein Interaction databases
IntAct (EBI)P10720
Ontologies - Pathways
Ontology : AmiGOprotein binding  extracellular space  inflammatory response  immune response  chemokine activity  heparin binding  platelet activation  neutrophil chemotaxis  leukocyte chemotaxis  CXCR chemokine receptor binding  antimicrobial humoral immune response mediated by antimicrobial peptide  chemokine-mediated signaling pathway  cellular response to lipopolysaccharide  
Ontology : EGO-EBIprotein binding  extracellular space  inflammatory response  immune response  chemokine activity  heparin binding  platelet activation  neutrophil chemotaxis  leukocyte chemotaxis  CXCR chemokine receptor binding  antimicrobial humoral immune response mediated by antimicrobial peptide  chemokine-mediated signaling pathway  cellular response to lipopolysaccharide  
Pathways : KEGGCytokine-cytokine receptor interaction    Chemokine signaling pathway   
REACTOMEP10720 [protein]
REACTOME PathwaysR-HSA-202733 [pathway]   
NDEx NetworkPF4V1
Atlas of Cancer Signalling NetworkPF4V1
Wikipedia pathwaysPF4V1
Orthology - Evolution
GeneTree (enSembl)ENSG00000109272
Phylogenetic Trees/Animal Genes : TreeFamPF4V1
Homologs : HomoloGenePF4V1
Homology/Alignments : Family Browser (UCSC)PF4V1
Gene fusions - Rearrangements
Fusion : QuiverPF4V1
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerPF4V1 [hg38]
Exome Variant ServerPF4V1
GNOMAD BrowserENSG00000109272
Varsome BrowserPF4V1
Genomic Variants (DGV)PF4V1 [DGVbeta]
DECIPHERPF4V1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisPF4V1 
ICGC Data PortalPF4V1 
TCGA Data PortalPF4V1 
Broad Tumor PortalPF4V1
OASIS PortalPF4V1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICPF4V1  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DPF4V1
Mutations and Diseases : HGMDPF4V1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch PF4V1
DgiDB (Drug Gene Interaction Database)PF4V1
DoCM (Curated mutations)PF4V1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)PF4V1 (select a term)
NCG6 (London) select PF4V1
Cancer3DPF4V1(select the gene name)
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry PF4V1
NextProtP10720 [Medical]
Target ValidationPF4V1
Huge Navigator PF4V1 [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTD
Pharm GKB GenePA33204
Clinical trialPF4V1
canSAR (ICR)PF4V1 (select the gene name)
DataMed IndexPF4V1
PubMed25 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Feb 19 17:57:22 CET 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us